4/11
08:37 am
inkt
This MiNK Therapeutics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
Low
Report
This MiNK Therapeutics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
4/8
12:13 pm
inkt
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR [Yahoo! Finance]
Low
Report
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR [Yahoo! Finance]
4/8
12:00 pm
inkt
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
High
Report
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
3/22
01:32 pm
inkt
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/21
11:43 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
3/21
07:17 am
inkt
MiNK Reports Fourth Quarter and Year-End 2023 Results [Yahoo! Finance]
Medium
Report
MiNK Reports Fourth Quarter and Year-End 2023 Results [Yahoo! Finance]
3/21
07:00 am
inkt
MiNK Reports Fourth Quarter and Year-End 2023 Results
Low
Report
MiNK Reports Fourth Quarter and Year-End 2023 Results
3/7
07:30 am
inkt
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
Medium
Report
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
3/6
08:51 am
inkt
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 [Yahoo! Finance]
Medium
Report
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 [Yahoo! Finance]
3/6
08:30 am
inkt
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Low
Report
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
2/14
08:00 am
inkt
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Medium
Report
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
2/6
08:19 am
inkt
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications [Yahoo! Finance]
Medium
Report
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications [Yahoo! Finance]
2/6
08:00 am
inkt
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Medium
Report
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
1/30
08:10 am
inkt
MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene [Yahoo! Finance]
Medium
Report
MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene [Yahoo! Finance]
1/30
08:00 am
inkt
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
Medium
Report
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene